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Solitary fibrous tumors are mesenchymal lesions that 
arise at a variety of sites, most commonly the pleura. 
Most patients are asymptomatic at diagnosis, with lesions 
being detected incidentally. Nevertheless, some patients 
present due to symptoms from local tumor compression 
(eg. of the airways and pulmonary parenchyma). 
Furthermore, radiological methods are not always 
conclusive in making a diagnosis, and thus, pathological 
analysis is often required. In the past three decades, 
immunohistochemical techniques have provided a 
gold standard in solitary fibrous tumor diagnosis. The 
signature marker of solitary fibrous tumor is the presence 
of the NAB2-STAT6 fusion that can be reliably detected 
with a STAT6 antibody. While solitary fibrous tumors 
are most often benign, they can be malignant in 10-20% 
of the cases. Unfortunately, histological parameters are 
not always predictive of benign vs malignant solitary 
fibrous tumors. As solitary fibrous tumors are generally 
regarded as relatively chemoresistant tumors; treatment 
is often limited to localized treatment modalities. The 
optimal treatment of solitary fibrous tumors appears 
to be complete surgical resection for both primary and 
local recurrent disease. However, in cases of suboptimal 
resection, large disease burden, or advanced recurrence, 
a multidisciplinary approach may be preferable. 
Specifically, radiotherapy for inoperable local disease 
can provide palliation/shrinkage. Given their sometimes 
-unpredictable and often- protracted clinical course, 
long-term follow-up post-resection is recommended.
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SOLITARY FIBROUS TUMORS OF CHEST: ANOTHER 
LOOK WITH THE ONCOLOGIC PERSPECTIVE
Solitary fibrous tumors (SFT) occur equally amongst men and 
women, and most often occur during middle age, although it 
is occasionally seen in younger people. About 70% of SFTs 
originate from thoracic structures, most often pleura (as was the 
case in the first-reported series described by Wagner in 1870) 
(1). SFTs have subsequently been described at almost every 
extrapleural anatomical site (2-4). The etiology of SFTs remains 
unknown, and no association has been demonstrated with 
environmental factors such as tobacco consumption or asbestos 
exposure (2). 
Pleural SFTs arise most frequently from the visceral (vs. the 
parietal or mediastinal) pleura. Pathological characteristics of 
SFTs of the pleura first described by Klemperer and Robin (5) 
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in 1931. Most tumors are slowly growing and are diagnosed 
incidentally as painless masses. However, although large 
tumors may cause local symptoms (e.g. pain and/or airway 
compression). Pathologically, SFTs can be either benign or 
malignant tumors (incidence ratio 7:1); however differentiation 
may be in conclusive (2,6).
Initial management of SFTs is largely surgical resection. The role 
of adjuvant treatment, or treatment for unresectable/recurrent 
disease, remains unclear and controversial, and warrants further 
investigation. We herein review the available English language 
literature and discuss the epidemiology, presentation, diagnosis, 
and treatment management of the malignant SFTs arising in the 
chest.
PATHOLOGY
SFT microscopically tend to appear with hypocellular collagen 
rich areas alternating with a proliferation of uniform elongated 
spindled cells in a distribution causally. SFTs generally have 
positive staining for vimentin, CD34, and cytokeratin-negative. 
In addition, CD99 and bcl-2 are positive in ≈50% of SFTs. Also, 
SFTs are generally negative for S-100, carcinoembryonic antigen, 
and smooth muscle actin (7). However, the pathologic findings 
are somewhat variable and classification is thus imperfect. 
A small percentage of SFTs possesses atypical features (8-10). 
Histological criteria to classify a SFT of the pleura as benign 
or malignant were described by England et al. (10) in 1989. 
These criteria include more than 4 mitoses per 10 high power 
fields, presence of necrosis, hypercellularity with crowding and 
overlapping of nuclei, and nuclear atypia. A tumor may have 
benign or malignant histologic features, but these features are 
not always predictive of the clinical behavior of the tumor (8-10). 
The distinction between diffuse malignant mesothelioma 
(DMM) and SFT is usually not difficult because most of the latter 
are histologically benign. However, the distinction between 
DMM and malignant SFT can be challenging. In this setting, 
the gross appearance can be helpful because DMMs typically 
cause diffuse pleural thickening, and SFTs are usually solitary/
localized masses, even when malignant. In addition, DMMs 
are positive for cytokeratin stains while SFTs are typically 
negative (although multifocal cytokeratin expression can be 
rarely occur). STAT6 is most often diagnostic of SFTs (11). In 
the light of recent developments, nuclear staining for STAT6 
becomes a pedestal method to make pathologic diagnosis of 
SFTs more accurate.
SYMPTOMS
More than 50% of the patients with SFT are asymptomatic, 
and the tumor is frequently an incidental finding on imaging. 
Symptoms, if any, are more frequently associated with larger/
central, and generally malignant, tumors. SFT may rarely 
present with systemic symptoms (hypoglycemia, hypertrophic 
osteoarthropathy), or non-specific symptoms (fever, weight 
loss, fatigue) (12).
Several series have demonstrated that chronic cough, chest pain 
and dyspnea were the most common complaints. Chest pain 
occurs more commonly in patients with tumor arising parietal 
pleura or invasion of parietal pleura or thoracic wall (2,12).
Hypertrophic pulmonary osteoarthropathy (HPO) (also 
known as, Bamberger-Marie syndrome or Osteoarthropathia 
hypertrophicans) symptom complex occurs in many thoracic 
disease processes. It has been described in as many as 20% of 
the SFT cases (9), particularly in larger tumors (e.g. >7 cm) (13). 
HPO can resolve post-surgery (14). Digital clubbing has been 
reported in all improve within 2-5 months (median 4 months) of 
surgery, but may reappear with tumor recurrence (14). 
Hypoglycemia, referred to as the Doege-Potter syndrome, 
apparently results from tumoral production of insulin-like 
growth factor II, and is reported to occur in a severe form in 
2-4% of patients with (often large) SFT (9,15). 
RADIOLOGY
SFT typically appear as masses abutting the pleura; most often 
arising from the lung visceral pleura (≈80% of cases) (13), 
but occasionally with apparent origins from the mediastinal 
(≈1-8% of cases) or parietal pleura (2,12,13,16,17). Given the 
close proximity of the various pleural surfaces to each other, 
the precise origin/extent of these lesions can be uncertain 
(Figure 1-4). The differential diagnosis typically includes 
mesothelioma, soft tissue sarcomas, and metastatic disease to 
the pleura (2,12). 
FIG. 1. CT scan of the chest showing a lobulated mass with 
heterogeneous enhancement, compressing the mediastinum, right main 
bronchus and right pulmonary artery.
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FIG. 2a, b. Axial CT and coronal PET-CT slices showing a huge malignant solitary fibrous tumor mass in the lower lobe of right lung.
FIG. 3. Axial CT slice of a solitary fibrous tumor located in anterior mediastinum.
FIG. 4a, b. Axial and coronal PET-CT slices of a solitary fibrous tumor located in mediastinum which slightly compressed trachea.
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Chest Radiography
On plain chest radiographs, SFTs appear as a homogeneous round 
mass, with smooth and well-defined margins. Pedunculated 
tumors may change the radiographic silhouette during breathing 
and decubital positioning. Usually the mass forms obtuse angles 
with the pleural surface, but in the case of large masses the 
angle may be acute. Pleural effusions are not typically seen and 
destruction of underlying bone occurs rarely (18).
Computed Tomography
Computed tomography (CT) scan is generally considered the 
optimal procedure to determine the size and location of the 
tumor, and is essential for surgical planning. CT attenuation 
depends on collagen content in these lesions. Thus, hyperdense 
lesions are typically collagen-rich, and low-attenuation regions 
represent necrosis or areas of myxoid or cystic degeneration 
(2,12,19). See Figure 1, 2, and 3 for examples. 
Magnetic Resonance Imaging
Magnetic resonance imaging (MRI) may be useful to evaluate 
SFT cases due to its excellent soft tissue resolution. MRI 
features of SFTs reflect the histologic findings and amount of 
fibrous tissue, necrosis, and hemorrhage. SFTs are typically 
characterized by low signal intensity on most MRI sequences, 
that is explained by the high collagen content within the tumor’s 
stroma and that may be helpful in making a preoperative 
differential diagnosis of a pleural-based mass. Thoracic SFTs 
typically have intermediate signal intensity on T1WI and 
heterogeneous low signal intensity on T2WI. Hyper intensity 
on T2WI is related to increased cellularity, edema, cystic 
degeneration, and hemorrhage. After gadolinium administration 
a marked heterogeneous enhancement is observed (2,20). 
Positron Emission Tomography
Fluoro-deoxy-glucose positron emission tomography (FDG 
PET) imaging can be helpful in differentiating more malignant 
conditions (e.g. lung cancers, pleural metastases, that are 
metabolically active on FDG PET) from SFT (that are largely 
indolent and not hypermetabolic on FDG PET). Large SFTs with 
increased FDG PET activity likely have a higher probability 
for malignancy, and in this setting the FDG PET might help 
to delineate the tumor extent local/regionally and distantly 
(example Figure 2 and 4) (21). Table 1 summarizes the general 
features of thoracic SFTs.
Response Evaluation
The Response Evaluation Criteria in Solid Tumors (RECIST) 
is a commonly used system to evaluate clinical treatment 
response based on changes in tumor size. Since some new 
targeted therapies, may cause tumor necrosis (with a decrease in 
tumor density but without a marked decrease in tumor size), the 
RECIST approach may not be optimal in this setting. Modified 
versions of the RECIST approach have been suggested that 
consider tumor size and imaging characteristics (e.g. Choi, 
or Positron Emission Tomography Response Criteria in Solid 
Tumors) and may be useful in evaluating response to treatment 
in patients with SFT (22,23). 
BIOPSY
Since these tumor arise from the pleural space, without direct 
contact with the airspaces, sputum cytology is usually not helpful. 
In the occasional case with a pleural effusion, cytology may show 
suspicious cells, but often is not diagnostic (24,25). Given the 
relative low cellularity of these lesions, making a histologic 
TABLE 1. Characteristics of SFTs of the thorax
Characteristics Properties Frequency
Location
Pleural
     Visceral
     Parietal
Mediastinal
Intrapulmonary
Chest wall    
80%
65%
15%
10%
10%
Rare
Clinic findings Airway compression symptoms, hypoglycemia, hypertrophic osteoartropathy
Imaging
Well-circumscribed, smooth, lobulated soft tissue 
Heterogeneous contrast enhancement**
Light microscopy
Fibroblast like cells 
No evidence of myogenous, epithelial, or neural differentiation
Immunohistochemistry
CD34*, Vimentin (+)
CD99 and bcl-2 (+) in 50% case
Generally, Keratin SMA, CEA, S100 and Actin (-)
SMA: smooth muscle antigen; CEA: carcinoembryonic antigen; SFT: solitary fibrous tumor; *Occasionally, malignant SFT may CD34 negative; **100% of malignant and 60% of 
benign SFT exhibit heterogeneous enhancement
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diagnosis can be challenging even when the gross lesion is directly 
sampled. For example, percutaneous transthoracic aspiration may 
be unsuccessful in distinguishing between malignant and benign 
disease, due to insufficient tumor sampling (26). Sung et al. (27) 
reported that they were able to obtain a definite preoperative 
diagnosis of SFT with fine needle aspiration biopsy in 43% of 
cases were. Tru-cut neddle biopsy has been associated with a 
higher yield of 100% (5 to 5) by Weynand et al. (28). SFTs do 
not appear to have a high potential for seeding. However, there 
is a theoretical risk of tumor seeding along the biopsy tract 
following transthoracic procedures, and indeed there is at least 
one such case report for SFT (29). Video-assisted thoracoscopic 
biopsy may be considered a more optimal approach to achieve a 
definitive diagnosis. Often, a definitive diagnosis is not obtained 
until review of the resected specimen (2,12).
TREATMENT
Surgery
Surgery of SFTs consists of an en bloc resection of the tumor 
surrounded by a margin of healthy tissue. Relatively small 
tumors can be resected via video assisted thoracoscopic 
surgery, whereas large tumors may require thoracotomy (7). 
Caution should be used to avoid contact between the tumor and 
the thoracoscopic sites, as seeding at the port sites has been 
reported (30).
Complete surgical resection is considered an important 
prognostic factor and surgical margins of 1 to 2 cm into 
healthy lung parenchyma from the tumor is recommended (13). 
Whereas pedunculated tumors can be safely resected with a 
wedge resection of the lung, large sessile tumors can be difficult 
to resect because of extensive adhesions, and may occasionally 
require a lobectomy or a pneumonectomy in order to achieve 
complete resection (31). Resection of the adjacent chest wall 
is done if there is gross involvement/adherence apparent at the 
time of surgery. In ≈ ≤3% of patients, the tumors are reported to 
be “inverted” and grow inside the lung parenchyma (32). These 
tumors often require a lobectomy (8,9). 
For localized recurrence of SFT, surgery may again be 
considered the optimal treatment. For patients with metastatic 
or technically inoperable SFTs, surgery may still play a role for 
palliation (e.g. relief of mass-related symptoms).
Radiotherapy
Adjuvant radiotherapy: The available literature is 
inconclusive with regard to the utility of postoperative 
radiotherapy (RT) for SFT treatment. Extrapolation of data 
from patients with soft tissue sarcomas might be reasonable. 
In patients with soft tissue sarcomas of the extremities, RT has 
been shown to decrease local recurrence (LR) rate following 
surgery (33). There are a few published retrospective series 
addressing adjuvant RT of thoracic soft tissue sarcomas 
(34,35). For example, Duranti et al. (34), described their 
experience treating 337 patients with thoracic localized soft 
tissue sarcoma. The mean patient age was 50 years and median 
tumor size was 8 cm. Location was soft tissue and chest wall 
in 85.5%, mediastinum 9.5%, and pleura 5%. The majority 
(51%) received adjuvant RT, and 41% received postoperative 
chemotherapy. With a median follow-up of 4.7 years, the 
5-year overall rate of LR rate was 14%. Radiation therapy 
was associated with better local control on both univariate and 
multivariate analysis (34).
In an analysis of 603 SFT cases (of 35% in thoracic localization) 
in the Surveillance, Epidemiology, and End Results database 
from 2000 to 2009, overall survival was similar for patients 
treated with surgery plus adjuvant RT compared to surgery 
alone. Given the nature of such population data, the patients 
in the different treatment groups were likely not similar. 
Presumably, the patients who received both RT and surgery had 
“worse tumors” (e.g. more likely close/positive margins) than 
those treated with surgery alone. Thus, the observation that the 
overall survivals are similar in the two treatment groups might 
suggest some utility to the RT. However, this is speculative. 
Nevertheless, this conclusion would be consistent with what we 
know from soft tissue sarcomas (36). 
Krengli et al. (37) summarized treatment results 102 patients 
with SFT of which 23% had thoracic disease. Local control was 
higher in patients who received surgery plus postoperative RT 
vs. surgery alone. 
RT has traditionally been used in patients with malignant 
SFT, narrow margins, large tumor size, or apparently-fast 
growing tumors. Histologically benign and completely 
resected tumors appear to have good outcomes irregardless 
of tumor size (31). However, tumors larger than 10 cm with 
malignant characteristics have been associated with a higher 
rate of disease recurrence. For example, de Perrot et al. (31) 
reported a recurrence rate maybe as high as 63% as for sessile 
malignant SFTs. In this patient group, postoperative RT should 
be considered even after complete resection. 
Anecdotal reports describe long-term survival in those 
undergoing postoperative RT in the setting of incomplete 
resection. For example, Suter at al. (26) published a case report 
of a patient with over 20-year disease free survival after subtotal 
resection followed by RT. It might be prudent to consider post-
operative RT in settings were a tumor recurrence might be 
expected to cause significant morbidity and/or not be readily 
amenable to re-resection. 
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TABLE 2. Reports of radiation therapy for SFT
Author 
(center)
Localization Number of patients Total dose (Fx 
size)
Target Response rate FU duration
Karapolat et 
al. (49)
2008
Pleura 1 30 Gy 
(3 Gy)
Subclinical disease No local failure Survive without failure at 
1 year
Saynak et al. 
(46)
2008
Pleura 1 60 Gy
(2 Gy)
Recurrent gross disease 60% response Died after 3 years without 
progression
Cardillo et 
al. (9)
2009
Pleura 4 Malignant SFT 
patients
Postoperative 
Radiotherapy
NS Subclinical disease No LF Survive without local failure 
at 13, 27, 42 and 47 months
Tanzi et al. 
(70)
2009
Pleura 2 NS Subclinical disease 1 local failure after 
2 years
(salvaged with 
surgery)
Survive without disease at 
22 months and 35 months
Shiono et al. 
(71)
2009
Pleura 1 NS Microscopic disease LF after 4 months Died after 7 months
Vanfleteren et 
al. (48)
2009
Pleura 1 42 Gy
(1.5 Gy BID)
Concurrent 
carboplatin/
etoposide
Gross disease 100% metabolic 
response
Survive without progression 
at 8 months
Filosso et al. 
(50)
2009
Pleura
(>10 cm size)
6 48-55 Gy
(Fraction size: 
NS)
Subclinical disease 1 LF 26 months 
after surgery
Survive all at 5-26 months 
follow-up
Baldi et al. 
(51)
2013
Pleura
Head and neck
Retroperitoneum
11 R1 Resection
3 have 
postoperative RT
45-60 Gy
(Fraction size: 
NS)
Microscopic
disease
No LF in 3 patients 
who received 
postoperative RT
NS 
Liu et al. (47)
2014
Pleura 1 50 Gy
(2 Gy)
10 Gy boost 
dose after 
evaluated 
response
Gross disease 44%
(By 50 Gy 
radiotherapy)
10 months 
Wushou et al.  
(36)
2015
35% Thoracic
613
RT + S (20) NS Gross disease NS Survive at median 
86 months FU
50%
S + RT (212) NS Subclinic/microscopic 
disease
59%
S alone (303) NA NA 60%
RT alone (21) NS Gross disease 33%
Krengli et al. 
2016 (37)
Abstract
23% Thoracic 52 S alone NA NA 52%
LF
67% 5 years 
actuarial
LC
67% 5 years OS
31 S + RT Median 50 Gy
45-66 Gy
(1.8-2.2 Gy)
Subclinical/
Microscopic disease
20%
LF
76% 5 years 
actuarial
LC
59% 5 years OS
9 RT alone Median 55 Gy
24-64 Gy
(2-4 Gy)
Gross disease 50%
LF
NS NS
NS: not stated; RT: radiotherapy; S: surgery; LF: local failure; OS: overall survival; NA: not applicable; FU: follow-up; SFT: solitary fibrous tumor
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A summary of reports using RT for SFT is provided in Table 
2. Overall, postoperative RT likely can improve local control 
probability; especially in patients with a relatively high risk of 
local failure (e.g. malignant histology and/or large tumor size, 
surgical margin positive disease).
Neoadjuvant radiotherapy: For soft tissue sarcomas, 
preoperative RT is often used sterilize the anticipated resection 
margins and improve local control. The potential theoretical 
advantages of preoperative RT include reduced potential for 
tumor seeding during surgery, better tumor oxygenation leading 
to improved radiosensitivity of the intact tumor, reducing the risk 
of close or positive margins (38), and smaller RT fields (vs. post-
operative RT). However, the use of pre-operative RT for SFTs is 
often limited by the difficulty of obtaining a precise preoperative 
diagnosis even with an open biopsy, and the unclear utility of this 
approach. 
Curative/Palliative radiotherapy: In those with unresectable 
or metastatic disease, RT may provide a palliative option 
symptomatic local disease (e.g. pain or airway compression).
Radiosensitivity and radiotherapy dose: Soft tissue sarcomas 
have often been erroneously labelled as “radio resistant”. This 
might be due to lack of clinically evident tumor shrinkage 
during RT. However, this lack of shrinkage might be reflective 
of the low cellularity, extensive necrosis, and dense fibrotic 
connective tissues, within many sarcomas, rather than the lack 
of RT-induced cell death. Indeed, clinical data suggest clinical 
efficacy as described. 
Clonagenic survival assays of human soft tissue sarcoma lines 
reveal no consistent evidence of intrinsic resistance to radiation. 
The surviving fraction at 2 Gy dose (SF2) has been accepted as 
a clinically relevant measure of radiation sensitivity. Several 
studies note SF2 values in the range of 0.124-0.39 (average 
0.24), similar (and perhaps even lower; i.e. more sensitive) to 
those seen in carcinomas (generally considered ‘radiosensitive’ 
base on changes in tumor size seen in the clinic) (38-41). 
In addition, the radiation doses that effectively reduce local 
failure following surgery for adenocarcinaoma of the breast, 
or squamous cell carcinoma of the cervix or head and neck, 
are similarly able to reduce local failure when combined with 
surgery for soft tissue sarcoma (42,43)
RT alone may provide local control in many patients (e.g. ≈30-
60%) with sarcoma who elect to not undergo recommended 
surgery or are deemed unsuitable for surgery (42). Similarly, 
RT alone (to ≈ 60-70 Gy) leads to responses in up to 50% 
of unresectable lesions (36,37). For certain radiosensitive 
histological subtypes (perhaps myxoid liposarcoma), pre-
operative RT may be particularly advantageous, as significant 
tumor shrinkage can be observed (42-44).
These observations suggest that the alleged “radioresistance” of 
sarcomas may be without basis.
For SFT, there are multiple case reports documenting clinical 
responses. For example, Kawamura et al. (45) reported a 
patient with a pelvic SFT with multiple lung metastases, who 
had significant response to 50 Gy pelvic RT. Saynak et al. (46) 
reported a significant response with 60 Gy thoracic RT in 30 
fractions in a patient with recurrent malignant SFT. Liu et 
al. (47) also reported a case where RT alone achieved a 44% 
decrease in tumor size, without evidence of progression at 10 
months follow-up post-RT. 
The pace of tumor shrinkage following RT is related to the 
underlying tumor kinetics. Tumors that grow rapidly tend to 
shrink rapidly, and vice versa. Given the relatively-indolent 
clinical course of SFT, one might expect RT-associated tumor 
shrinkage to be delayed (i.e. more than a few weeks/months). 
Indeed, in the four case reports of tumor response following RT, 
the maximum response was seen at ≈3-10 months post-RT (45-
48). Some curative/palliative RT experiences are summarized 
in Table 2.
The optimal pre/post-operative RT doses in patients with SFT is 
unclear, and extrapolation from other tumor sites is reasonable. 
The literature reported post-operative doses usually range from 
45-60 Gy (37,49-51). In cases where the perceived risk of LR 
is higher (e.g. close margins), it is reasonable to more-routinely 
consider using higher doses (eg, 54-60 Gy or even 60-66 Gy for 
positive margins) (43,51). In these settings, we advise that the 
RT fields be made as tight as possible to minimize the incidental 
doses to normal tissues. Newer technologies such as IMRT/
IGRT techniques can be used to more accurately deliver RT. 
For soft tissue sarcomas, the standard regimen for pre-operative 
RT is 45-50 Gy, in 1.8-2 Gy fractions, followed by surgery 
approximately 6 weeks following completion of RT, and this 
same approach might be warranted if pre-operative RT were to 
be used for SFT (43). 
SYSTEMIC TREATMENT
Data regarding the effectiveness of systemic therapy for SFT is 
limited (Tables 3, 4). In general, the reported response rates are 
low. However, results are perhaps somewhat more encouraging 
with Dacarbazine, or some of the newer targeted agents (52-
59). 
PROGNOSIS
The prognosis for SFT is variable. Broadly speaking, worse 
prognosis has been associated with large size, malignant 
histology and pathologic characteristics (7,9,14,27,60-72) (See 
Table 5). 
Tapias et al. (68) proposed a scoring system which combines 
common clinical and histological features able to predict the 
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recurrence after (radical) surgical resection for thoracic SFTs. 
Their criteria were pleural origin (visceral/intrapulmonary 
or parietal), morphology (pedunculated or sessile), size (<10 
cm or ≥10 cm), hypercellularity, necrosis or hemorrhage and 
mitosis number (<4 or ≥4). They assigned one point for each 
unfavorable variable. In their analysis, a sum of <3 points 
was associated with a low risk of recurrence (e.g. 3.5% at 15 
years) compared with recurrence rate of 28% in patients with 
≥3 points. They found that the presence of a pleural effusion, 
as well as a symptomatic presentation, and a Ki67 proliferation 
index >10% were associated with SFT recurrence on univariate 
analysis. Unfortunately, these variables could not be included in 
this regression models given the paucity of events and the small 
sample size (67). This new risk stratification model will need to 
be validated in other cohort studies.
The 10-year overall survival rate varies between 54 and 89% 
among published series (7,9,14,27,60-67). Metastatic disease 
is often only appreciated 10-20 years after initial diagnosis, 
and bone, lung, and liver appear to be common sites of 
metastatic disease. Thoracic metastases are discovered in 
0-36% and extra-thoracic metastases are found in 0-19% of 
patients with pleural based SFT (2,12). Unfortunately, most 
patients with recurrent disease survive less than 5 years (7). 
Despite systemic therapy, patients with metastatic disease 
have a poor prognosis with median survival ranging from 22 
to 46 months (52,54).
Published large series demonstrated that one of the most 
important prognostic factor is whether the tumor can be 
completely excised initially (10). Unfortunately, even 
completely removed lesions may recur. LRs may occur even 
TABLE 3. Reports of conventional chemotherapy for SFT
Study n Drugs
RECIST
Median PFS
(months)PR SD
n % n %
Constantinidou et al. (54)
2011
17 Antracycline-based 1 6 7 41
4.2
7 Non-antracycline 0 5 71
Levard et al. (58)
2013
23 Cytotoxic 2 9 13 57 5.2
Stacchiotti et al. (53)
2013
30 Antracycline-based 6 20 8 27 4
Stacchiotti et al. (52)
2013
8 Dacarbazine 3 38 4 50 7
Park et al. (55)
2013
25
18 first-line
15 Doxorubicin-based
5 Gemcitabine-based
5 Paclitaxel
0 16 89 4.6
Khalifa et al. (72)
2015
11
Trabectedin
8, 2nd line
3, 3rd line
1 9 8 73 11.6
SFT: solitary fibrous tumor; n: patient number; RECIST: Response Evaluation Criteria In Solid Tumors; PR: partial response; SD: stable disease; PD: progressive disease; PFS: 
progression-free survival
TABLE 4. Reports of targeted agents for SFT
Study n Drug
Response
Median PFS
(RECIST/
Choi)
month
RECIST Choi criteria
Partial response Stable disease Partial response Stable disease
n %  n % n % n %
Stacchiotti et al. (56)
2012
31
25 prior ChT
Sunitinib malate 2 6.5 17 54 14 48 5 17 6
Levard et al. (58)
2013
10 
2nd, 3rd or 4th line
Sunitinib or 
Pazopanib 0 0 5 50 NS NS NS NS 5.1
Stacchiotti et al. (57)
2014
6 Pazopanib 0 0 3 50 1 17 2 33 3
SFT: solitary fibrous tumor; n: patient number; RECIST: Response Evaluation Criteria In Solid Tumors; PR: partial response; SD: stable disease; PD: progressive disease; PFS: 
progression-free survival; NS: not stated
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TABLE 5. Tumor characteristics associated with a poorer prognosis in surgical series published after malignancy criteria defined (1989)
Author (center)/
publication year
Number of 
patients
(malignant/benign 
histology)
Complete 
resection 
rate (%)
Adverse prognostic characteristic 
reported Endpoint
Results if 
prognostic factor 
present 
Results if 
prognostic factor 
absent 
England et al. (10)
1989
171  
37/134 100 Malignant histology
OS
Median 31 months 
and 57 months 
FU, respectively
45%* 100%*
Witkin and Rosai 
(60)
1989
11^ 7/4 NS
Large size
hypercellularity
≥1 mitoses/10 HPF
hemorrhage
Failure 36% 64%
Rena et al. (14)
2001
21  
7/14 100 Malignant histology OS at 5 years 100%^^^^ 100%
Magdeleinat et 
al. (7)
2002
60  
22/38 100 Malignant histology
OS at 5 and 10 
years 89% 97%
Sung et al. (27)
2005
63  
44/19 97 Malignant histology
OS at 30 moths 
and 19 months 
FU, respectively
58%* 100%*
Carretta et al. (61)
2006
18  
2/16 100
Malignant histology, 
Sessile morphology, 
Lower expression of progesterone 
receptors
DFS at 5 years
80% for all patients
Not separately specified for the 
subgroups
Schirosi et al. (62)
2008
88 
 (NS) 100
≥4 mitoses/10 HPF, Necrosis, 
High p53 expression
(Multivariate analysis)
OS at 5 years
82% for all patients
Not separately specified for the 
subgroups
Harrison-Phipps et 
al. (63)
2009
84  
11/73 100 Malignant histology OS at 5 years 45% 89%
Milano et al. (64)
2011
77  
77/0 43
Stage 
(nodal or distant metastasis) 
No surgery
OS at 5 years 49% not separately specified for the subgroups
Cardillo et al. (9)
2009
110  
15/95 100 Malignant histology DFS at 10 years 67% 96%
Lococo et al. (65)
2012
50 50/0 92
Chest wall invasion
DFS at 5 years
50% 80%
Malignant pleural effusion 56% 79%
Incomplete resection
OS at 5 years
0 87%
Malignant pleural effusion 70% 86%
Lahon et al. (66)
2012
157  
67/90 100 Malignant histology OS at 5 years 68% 96%
Demicco et al. 
(67)
2012
103^^
100
Age ≥55 years, 
Size ≥15 cm, 
≥4 mitosis/10 HPF, 
Necrosis
MFS at 5 years 
15%
(moderate/high risk) 
77%
(low risk)
Tapias et al. (68)
2013
59  
14/45 100
Size >10 cm (Multivariate analysis)
Parietal origin, 
Sessile, 
Hypercellularity, 
Necrosis or hemorrhage, 
≥4 mitosis/10 HPF (univariate 
analysis)
Failure rate at 10 
years
77%
score of ≥3^^^^^
0
score of <3^^^^^
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after 5 years after surgical operation. Recurrence after complete 
resection of a benign SFT can be either benign or malignant. 
Most patients who have recurrence in the setting of malignant 
disease survive less than 5 years (2,7,12).
In conclusion, 1. SFT is a fibroblastic mesenchymal neoplasm 
that arises in both thoracic and extrathoracic sites. Thoracic 
forms are generally asymptomatic at the time of diagnosis, and 
the radiographic features are a well-circumscribed, peripheral 
mass that abuts the pleural surface, frequently attached by 
a pedicle. Pediculated and sessile SFTs of thoracic sites 
commonly grow into the pleural cavity; however, some rare 
cases grow into the lung parenchyma. 
2. Occasionally larger lesions may cause local symptoms (e.g. 
cough, chest pain and dyspnea). 
3. Approximately 10% to 20% of SFTs are histologically classified 
as malignant (e.g. with increased mitoses, necrosis, atypia, and 
hypercellularity), and these may be hyperactive on PET. 
4. Histological and morphological characteristics are often 
predictive of outcome. Malignant SFTs have a higher recurrence 
rate and mortality rate (up to ≈30% in some series). 
5. Surgical excision has been the standard treatment option for 
both benign and malignant SFTs, and is both diagnostic and 
therapeutic. The role of adjuvant RT or chemotherapy is unclear. 
Nevertheless, RT can be considered in cases of SFTs with 
malignant features, especially in the presence of incomplete 
excision.
6. Some newer systemic agents (e.g. sunitinib, sorafenib and 
bevacizumab) may be helpful for patients with unresectable 
or metastatic tumors. Post-treatment imaging can show tumor 
devascularization detectable on scans without much size change 
in tumor volumes, and thus the classic RECIST criteria may not 
be optimal in quantifying response. Modified RECIST crieteria 
might be more appropriate.
7. Reports suggest that RT can provide an apparent responsive 
effect on SFTs in similar fashion to other soft tissue sarcomas. 
Inoperable/recurrent localized disease may also be treated with RT. 
8. SFTs can have very late recurrences (>15 years), and this 
long-term clinical follow-up is recommended.
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